Syros stock craters after lead cancer therapy flops in Phase III trial
The company plans to discontinue the study after the combination therapy failed to meet the primary endpoint in the Phase III trial.
13 November 2024
13 November 2024
The company plans to discontinue the study after the combination therapy failed to meet the primary endpoint in the Phase III trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.